Brokerages Expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to Announce -$0.71 Earnings Per Share

Equities research analysts forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) will post earnings of ($0.71) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Checkmate Pharmaceuticals’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.71). Checkmate Pharmaceuticals posted earnings per share of ($0.84) in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.5%. The business is scheduled to issue its next earnings results on Friday, November 12th.

On average, analysts expect that Checkmate Pharmaceuticals will report full-year earnings of ($2.95) per share for the current financial year, with EPS estimates ranging from ($3.00) to ($2.89). For the next financial year, analysts anticipate that the firm will report earnings of ($2.65) per share, with EPS estimates ranging from ($3.09) to ($2.20). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Checkmate Pharmaceuticals.

Checkmate Pharmaceuticals (NASDAQ:CMPI) last issued its quarterly earnings data on Thursday, August 12th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14).

A number of brokerages recently weighed in on CMPI. Bank of America raised Checkmate Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Wednesday, October 6th. Zacks Investment Research downgraded Checkmate Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 17th.

CMPI stock traded up $0.04 during trading on Monday, reaching $4.07. 34 shares of the company traded hands, compared to its average volume of 38,829. Checkmate Pharmaceuticals has a 12 month low of $3.63 and a 12 month high of $23.10. The business has a 50 day simple moving average of $4.87 and a 200 day simple moving average of $6.11. The company has a market capitalization of $88.03 million, a price-to-earnings ratio of -0.90 and a beta of 1.35.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in Checkmate Pharmaceuticals in the second quarter worth about $241,000. Alberta Investment Management Corp acquired a new stake in Checkmate Pharmaceuticals in the second quarter worth about $149,000. Renaissance Technologies LLC acquired a new stake in Checkmate Pharmaceuticals in the second quarter worth about $140,000. Advisory Services Network LLC acquired a new stake in Checkmate Pharmaceuticals in the second quarter worth about $46,000. Finally, Ergoteles LLC acquired a new stake in Checkmate Pharmaceuticals in the second quarter worth about $158,000. 75.49% of the stock is owned by institutional investors and hedge funds.

Checkmate Pharmaceuticals Company Profile

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Recommended Story: History of the Euro STOXX 50 Index

Get a free copy of the Zacks research report on Checkmate Pharmaceuticals (CMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.